MX2020007406A - Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. - Google Patents
Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.Info
- Publication number
- MX2020007406A MX2020007406A MX2020007406A MX2020007406A MX2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A MX 2020007406 A MX2020007406 A MX 2020007406A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- same
- antigen
- binding fragment
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un novedoso anticuerpo contra PD-L1, un fragmento de union al antigeno del mismo, y un uso farmaceutico de los mismos; un anticuerpo humanizado que comprende una CDR del anticuerpo contra PD-L1, una composicion farmaceutica que comprende el anticuerpo contra PD-L1 y el fragmento de union al antigeno del mismo, y un uso del anticuerpo contra PD-L1 como un farmaco; y un uso de un anticuerpo contra PD-L1 humanizado en la preparacion de un farmaco para tratar enfermedades o trastornos asociados con PD-L1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810023267 | 2018-01-10 | ||
| PCT/CN2019/070982 WO2019137397A1 (zh) | 2018-01-10 | 2019-01-09 | Pd-l1抗体、其抗原结合片段及医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007406A true MX2020007406A (es) | 2020-09-14 |
Family
ID=67219311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007406A MX2020007406A (es) | 2018-01-10 | 2019-01-09 | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11359021B2 (es) |
| EP (1) | EP3741777A4 (es) |
| JP (1) | JP2021510078A (es) |
| KR (1) | KR20200108306A (es) |
| CN (1) | CN111278861B (es) |
| AU (1) | AU2019206958A1 (es) |
| BR (1) | BR112020013475A2 (es) |
| CA (1) | CA3087105A1 (es) |
| MX (1) | MX2020007406A (es) |
| TW (1) | TWI717678B (es) |
| WO (1) | WO2019137397A1 (es) |
| ZA (1) | ZA202004907B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004804A1 (en) * | 2015-11-17 | 2017-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
| CN110760517B (zh) * | 2019-10-09 | 2022-04-29 | 天津大学 | 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用 |
| WO2022121846A1 (zh) * | 2020-12-08 | 2022-06-16 | 博际生物医药科技(杭州)有限公司 | Pd-l1抗体及其应用 |
| TWI789679B (zh) * | 2021-01-12 | 2023-01-11 | 大陸商江蘇先聲藥業有限公司 | 抗人程序性死亡配體-1（pd-l1）的抗體及其用途 |
| CN115181180B (zh) * | 2021-03-03 | 2025-07-04 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1（pd-l1）的抗体及其应用 |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| WO2023046113A1 (zh) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| CN115925937A (zh) * | 2022-08-05 | 2023-04-07 | 赛灵药业科技集团股份有限公司北京分公司 | 一种抗体或其片段及其制药用途 |
| CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
| WO2025201522A1 (zh) * | 2024-03-29 | 2025-10-02 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体药物偶联物治疗肿瘤 |
| CN120081943A (zh) * | 2024-04-16 | 2025-06-03 | 赛业（苏州）生物科技有限公司 | 一种人源化pd-l1抗体及其应用 |
| WO2025252203A1 (zh) * | 2024-06-06 | 2025-12-11 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体药物偶联物治疗肿瘤的用途 |
| CN119954956B (zh) * | 2025-02-05 | 2025-08-22 | 可蓝赛生物医药(上海)有限公司 | 一种nk细胞的制备方法及其在治疗癌症中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| BR112015023120A2 (pt) | 2013-03-15 | 2017-11-21 | Genentech Inc | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado |
| TN2015000444A1 (en) | 2013-06-03 | 2017-04-06 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| MY175472A (en) | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| KR102476226B1 (ko) * | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| CN105777906B (zh) | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN106243225B (zh) | 2015-06-11 | 2021-01-19 | 智翔（上海）医药科技有限公司 | 新型抗-pd-l1抗体 |
| CA3004804A1 (en) * | 2015-11-17 | 2017-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof |
| CN107216389B (zh) * | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
| SG11201809336QA (en) * | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| CN106699891B (zh) | 2017-01-25 | 2019-04-09 | 北京天广实生物技术股份有限公司 | 一种抗pd-l1抗体、其药物组合物及其用途 |
| CN107365383B (zh) * | 2017-07-12 | 2019-04-30 | 苏州大学附属第一医院 | 一种人源化抗人pd-1单克隆抗体及其制备方法、用途与药物 |
| WO2019129136A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
-
2019
- 2019-01-09 EP EP19738076.9A patent/EP3741777A4/en not_active Withdrawn
- 2019-01-09 WO PCT/CN2019/070982 patent/WO2019137397A1/zh not_active Ceased
- 2019-01-09 JP JP2020538638A patent/JP2021510078A/ja not_active Ceased
- 2019-01-09 KR KR1020207022689A patent/KR20200108306A/ko not_active Ceased
- 2019-01-09 CA CA3087105A patent/CA3087105A1/en active Pending
- 2019-01-09 MX MX2020007406A patent/MX2020007406A/es unknown
- 2019-01-09 US US16/960,297 patent/US11359021B2/en active Active
- 2019-01-09 AU AU2019206958A patent/AU2019206958A1/en not_active Abandoned
- 2019-01-09 CN CN201980005432.2A patent/CN111278861B/zh active Active
- 2019-01-09 BR BR112020013475-9A patent/BR112020013475A2/pt not_active IP Right Cessation
- 2019-01-10 TW TW108101001A patent/TWI717678B/zh not_active IP Right Cessation
-
2020
- 2020-08-07 ZA ZA2020/04907A patent/ZA202004907B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3741777A4 (en) | 2021-10-13 |
| EP3741777A1 (en) | 2020-11-25 |
| US20200339692A1 (en) | 2020-10-29 |
| AU2019206958A1 (en) | 2020-07-16 |
| RU2020124261A (ru) | 2022-01-25 |
| US11359021B2 (en) | 2022-06-14 |
| WO2019137397A1 (zh) | 2019-07-18 |
| CN111278861A (zh) | 2020-06-12 |
| BR112020013475A2 (pt) | 2020-12-08 |
| TWI717678B (zh) | 2021-02-01 |
| RU2020124261A3 (es) | 2022-01-25 |
| CA3087105A1 (en) | 2019-07-18 |
| JP2021510078A (ja) | 2021-04-15 |
| ZA202004907B (en) | 2022-10-26 |
| KR20200108306A (ko) | 2020-09-17 |
| CN111278861B (zh) | 2022-05-27 |
| TW201930360A (zh) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| MX2025001902A (es) | Construcciones de anticuerpos anti-ror | |
| BR112021008873A8 (pt) | Formulação | |
| MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| JOP20200177A1 (ar) | طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2018006782A (es) | Nuevos anticuerpos anti-claudina y sus metodos de uso. | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
| MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
| MX2022003668A (es) | Metodos y composiciones para el tratamiento de la retinopatia diabetica. | |
| MX2022006784A (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
| ZA202201946B (en) | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |